AU733938B2 - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors Download PDF

Info

Publication number
AU733938B2
AU733938B2 AU33422/97A AU3342297A AU733938B2 AU 733938 B2 AU733938 B2 AU 733938B2 AU 33422/97 A AU33422/97 A AU 33422/97A AU 3342297 A AU3342297 A AU 3342297A AU 733938 B2 AU733938 B2 AU 733938B2
Authority
AU
Australia
Prior art keywords
group
methyl
phenyl
ethyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33422/97A
Other languages
English (en)
Other versions
AU3342297A (en
Inventor
Francesca Abrate
Marco Alpegiani
Pierluigi Bissolino
Massimiliano Palladino
Ettore Perrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of AU3342297A publication Critical patent/AU3342297A/en
Application granted granted Critical
Publication of AU733938B2 publication Critical patent/AU733938B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33422/97A 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors Ceased AU733938B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9613547.0A GB9613547D0 (en) 1996-06-27 1996-06-27 Matrix metalloproteinase inhibitors
GB9613547 1996-06-27
PCT/EP1997/003251 WO1997049674A1 (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
AU3342297A AU3342297A (en) 1998-01-14
AU733938B2 true AU733938B2 (en) 2001-05-31

Family

ID=10796022

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33422/97A Ceased AU733938B2 (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Country Status (18)

Country Link
EP (1) EP0920414A1 (es)
JP (1) JP2000514043A (es)
KR (1) KR20000022534A (es)
AR (1) AR008621A1 (es)
AU (1) AU733938B2 (es)
BR (1) BR9709902A (es)
CA (1) CA2257404A1 (es)
CZ (1) CZ430398A3 (es)
EA (1) EA001432B1 (es)
GB (1) GB9613547D0 (es)
ID (1) ID17792A (es)
IL (1) IL127262A0 (es)
NO (1) NO986049L (es)
NZ (1) NZ333550A (es)
PL (1) PL330897A1 (es)
TW (1) TW460441B (es)
WO (1) WO1997049674A1 (es)
ZA (1) ZA975631B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
GB9803005D0 (en) * 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804777D0 (en) * 1998-03-07 1998-04-29 British Biotech Pharm Anti-inflammatory agents
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
GB9901863D0 (en) 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
AU764051B2 (en) 1999-03-03 2003-08-07 Procter & Gamble Company, The Alkenyl- and alkynyl-containing metalloprotease inhibitors
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ES2283589T3 (es) 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
KR20060116552A (ko) * 2005-05-10 2006-11-15 연세대학교 산학협력단 매트릭스 메탈로프로테이나제 저해제로서 엔-포르밀히드록실아민 유도체
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
CN108383804A (zh) 2009-11-12 2018-08-10 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497192A2 (en) * 1991-02-01 1992-08-05 F. Hoffmann-La Roche Ag Amino acid derivatives
EP0236872B1 (de) * 1986-03-11 1992-11-25 F. Hoffmann-La Roche Ag Hydroxylaminderivate, deren Herstellung und Verwendung für Heilmittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
KR927003520A (ko) * 1990-12-03 1992-12-18 죤 에드워드 베리만 펩티딜(peptidyl) 유도체
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236872B1 (de) * 1986-03-11 1992-11-25 F. Hoffmann-La Roche Ag Hydroxylaminderivate, deren Herstellung und Verwendung für Heilmittel
EP0497192A2 (en) * 1991-02-01 1992-08-05 F. Hoffmann-La Roche Ag Amino acid derivatives

Also Published As

Publication number Publication date
KR20000022534A (ko) 2000-04-25
CZ430398A3 (cs) 1999-08-11
IL127262A0 (en) 1999-09-22
GB9613547D0 (en) 1996-08-28
AU3342297A (en) 1998-01-14
NO986049D0 (no) 1998-12-22
CA2257404A1 (en) 1997-12-31
BR9709902A (pt) 1999-08-10
EA001432B1 (ru) 2001-02-26
ID17792A (id) 1998-01-29
NO986049L (no) 1999-03-01
TW460441B (en) 2001-10-21
NZ333550A (en) 2000-07-28
EA199900057A1 (ru) 1999-06-24
EP0920414A1 (en) 1999-06-09
PL330897A1 (en) 1999-06-07
AR008621A1 (es) 2000-02-09
ZA975631B (en) 1998-01-30
WO1997049674A1 (en) 1997-12-31
JP2000514043A (ja) 2000-10-24

Similar Documents

Publication Publication Date Title
AU733938B2 (en) Matrix metalloproteinase inhibitors
EP0960108B1 (en) Matrix metalloproteinase inhibitors
EP0950656B1 (en) Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
AU725058B2 (en) Aminoguanidines and alkoxyguanidines as protease inhibitors
WO1999002510A1 (en) Matrix metalloproteinase inhibitors
CA2285405A1 (en) Amidoaromatic ring sulfonamide hydroxamic acid compounds
EP0725059B1 (en) 2,3-diaminopropionic acid derivative
AU2006228957A1 (en) Inhibitors of histone deacetylase
JP2001521504A (ja) メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用
WO2008053913A1 (fr) Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
EP0865339B1 (en) Metalloproteinase inhibitors
EP0748313A1 (en) Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
AU2006326256B2 (en) (2,5-dioxoimidazolidin-I-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors
WO1997003783A9 (en) Metalloproteinase inhibitors
AU2003297364B2 (en) Inhibitors of TACE
US6482827B1 (en) Matrix metalloproteinase inhibitors
US6277876B1 (en) Matrix metalloproteinase inhibitors
WO1998023588A9 (en) Metalloproteinase inhibitors
KR20020038951A (ko) 베타 이치환된 메탈로프로테아제 저해제
WO1998023588A1 (en) Metalloproteinase inhibitors
MXPA98010329A (es) Inhibidores de metaloproteinasas de matriz
CA2434205A1 (en) 1,1-disubstituted cyclic inhibitors of matrix metalloprotease and tnf-.alpha.
CA2417914A1 (en) Cyclic oxyguanidine protease inhibitors
EP0432975A1 (en) Cyclic renin inhibitors
PL173030B1 (pl) Nowe sulfonamidokarboksamidy i sposób ich wytwarzania

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired